Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 370.53M | 440.55M | 491.12M | 526.30M | 546.22M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 9.07M | 9.50M | 8.71M | 7.87M | 8.46M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 379.59M | 450.05M | 499.82M | 534.17M | 554.69M |
|
|
|||||
| Total Current Assets | 379.59M | 450.05M | 499.82M | 534.17M | 554.69M |
| Net Property, Plant & Equipment | 72.94M | 124.71M | 130.79M | 136.53M | 142.32M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.31M | 5.35M | 4.53M | 4.52M | 4.52M |
| Total Assets | 490.86M | 619.22M | 654.14M | 694.22M | 750.03M |
|
|
|||||
| Total Accounts Payable | 5.37M | 3.60M | 4.20M | 4.90M | 4.82M |
| Total Accrued Expenses | 29.37M | 21.88M | 18.77M | 18.25M | 20.36M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 7.97M | 7.13M | 6.90M | 6.67M | 6.27M |
| Total Finance Division Other Current Liabilities | 11.08M | 907.00K | 1.01M | 2.54M | 3.07M |
| Total Other Current Liabilities | 11.08M | 907.00K | 1.01M | 2.54M | 3.07M |
| Total Current Liabilities | 53.79M | 33.51M | 30.88M | 32.35M | 34.52M |
|
|
|||||
| Total Current Liabilities | 53.79M | 33.51M | 30.88M | 32.35M | 34.52M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 50.99M | 51.44M | 53.32M | 55.16M | 56.89M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 3.25M | 3.57M | 3.44M | 3.55M | 3.66M |
| Total Liabilities | 108.04M | 88.52M | 87.64M | 91.06M | 95.08M |
|
|
|||||
| Common Stock & APIC | 1.73B | 1.68B | 1.68B | 1.67B | 1.66B |
| Retained Earnings | -1.35B | -1.15B | -1.11B | -1.06B | -1.00B |
| Treasury Stock & Other | 291.00K | 760.00K | -397.00K | -404.00K | -94.00K |
| Total Common Equity | 382.82M | 530.70M | 566.50M | 603.16M | 654.95M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 382.82M | 530.70M | 566.50M | 603.16M | 654.95M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 382.82M | 530.70M | 566.50M | 603.16M | 654.95M |
|
|
|||||
